| 產(chǎn)品名稱 | BT142 mut/- |
|---|---|
| 商品貨號(hào) | B228265 |
| Organism | Homo sapiens, human |
| Tissue | Brain |
| Cell Type | Neural |
| Product Format | frozen |
| Morphology | Neurosphere |
| Culture Properties | Suspension |
| Biosafety Level | 1 [It is the responsibility of the investigator to determine appropriate safety procedures for use with this material. As a reference, laboratory safety is discussed in the publication Biosafety in Microbiological and Biomedical Laboratories and can be accessed by searching "BMBL" at www.cdc.gov.]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Oligoastrocytoma Grade III |
| Age | 38 years |
| Gender | Male |
| Ethnicity | Caucasian |
| Storage Conditions | Liquid Nitrogen Vapor Phase |
| Images |  |
| Clinical Data | 38 years Male Caucasian Oligoastrocytoma Grade III |
| Comments | Point mutations in isocitrate dehydrogenase I (IDH1) and IDH2 are found in majority of grade II and III gliomas. R132H is the most common IDH1 substitution found in gliomas. BT142 mut/- contains a homozygous IDH1 R132H mutation, which originated from a heterozygous IDH1 R132H BT142 cells. The cells grow as phase-bright, smooth spheres. The neurospheres should not get too big, ragged or dark as this is a sign of unhealthy, dying cells. The cells should be passaged when the neurospheres are 200 to 400 µm in size. |
| Complete Growth Medium | There are two options for the base medium for this cell line. Option 1: NeuroCult NS-A Proliferation kit (Catalog No. 5751, Stem Cell Technologies) Option 2: DMEM/F12 (1:1) (Catalog No. 30-2006, ATCC) with an additional 0.9% glucose, 4 mM L-glutamine (Catalog No. 30-2214, ATCC), 25 µg/mL insulin, 100 µg/mL transferrin, 20 nM progesterone, 15 µM putrescine and 30 nM selenite To make the complete growth medium, add the following supplements to either options of the base medium (see above):
|
| Subculturing | The cells grow as phase-bright, smooth spheres. The neurospheres should not get too big, ragged or dark as this is a sign of unhealthy, dying cells. The cells should be passaged when the neurospheres are about 200-400 μm in size. Volumes used in this protocol are for 75 cm2 flask.
Note: If accurate cell count is necessary, Accumax (Catalog No. AM105, Innovative Cell Technologies) can be used; however, the cells may take some time to recover from an enzymatic dissociation.
|
| Cryopreservation | Freeze medium: Complete growth medium (90%) supplemented with 10% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Name of Depositor | This cell line was deposited by Samuel Weiss, Ph.D. and Gregory Cairncross, Ph.D. of the University of Calgary |
| References | Luchman HA et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol. 14:184-191, 2012. PubMed: 22166263 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
